Diary - News
All news Alizé Pharma will present clinical results
Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, will present the results from two Phase I clinical trials with its unacylated ghrelin analog AZP-531 during the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston on June 5-9,2015.